Scientific Games (NASDAQ:SGMS) has gained 0.22% or two cents a share to settle at $9.09 with a volume of 290,000 shares. For the past 52 weeks the stock has been trading between $6.58 and $15.09 with an average volume of 700,000 shares. Company has a market cap of $836 million and a beta of 1.77.
Scientific Games Corporation (Scientific Games) is a global supplier of products and services to lotteries, and a provider of gaming technology and content to other gaming operators worldwide. The Company reports its operations in three segments: Printed Products Group, Lottery Systems Group and Diversified Gaming Group. Printed Products Group is a provider of instant lottery tickets in the world. The Company's Lottery Systems Group is a provider of customized computer software, software support, equipment and data communication services to government sponsored and privately operated lotteries in the United States and internationally.
Bayer AG (PINK:BAYRY) has lost 0.52% or $.41 a share to settle at $77.72 with a volume of 56,000 shares. For the past 52 weeks the stock has been trading between $53.63 and $80.40 with an average volume of 57,000 shares. Company has a market cap of $64.27 billion and a beta of 1.07.
Bayer AG is a German management holding company with core competencies in the field of health care, nutrition and high-tech materials. The Company's business operations are organized into three subgroups: HealthCare, CropScience and MaterialScience, supported by the service companies Bayer Business Services, Bayer Technology Services and Currenta. Bayer HealthCare is involved in the research, development and manufacture of health products for people and animals.
genomic Health, Inc. (NASDAQ:GHDX) has gained 1.16% or $.30 a share to settle at $26.18 with a volume of 213,000 shares. For the past 52 weeks the stock has been trading between $11.94 and $26.53 with an average volume of 172,000 shares. Company has a market cap of $755 million and a beta of 0.56.
Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer. The Company's Oncotype DX platform utilizes quantitative genomic analysis in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. Its Oncotype DX breast cancer test has extensive clinical evidence validating its ability to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit.
Arrow Electronics, Inc. (NYSE:ARW) has lost 2.71% or $1.09 a share to settle at $39.17 with a volume of 830,000 shares. For the past 52 weeks the stock has been trading between $21.76 and $14.90 with an average volume of 1.4 million shares. Company has a market cap of $4.5 billion and a P/E ratio of 9.74.
Arrow Electronics, Inc. (Arrow), incorporated in 1946, is a provider of products, services and solutions to industrial and commercial users of electronic components and enterprise computing solutions. Arrow serves over 900 suppliers and over 125,000 original equipment manufacturers (OEMs), contract manufacturers (CMs) and commercial customers.
OTCPicks.com is not a registered investment advisers or broker/dealer. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. Always do you own homework before investing in any stock.
Forward-Looking Statement: This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
Disclosure: OTCpicks.com has not been compensated for any current or recent stocks listed in this stock news report
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/press_release_distribution_lists.php.